{"filing":{"accession_number":"0001104659-26-106137","cik":"0001818838","ticker":"ADAG","company_name":"Adagene Inc.","form":"6-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"tm2624926d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818838/000110465926106137/tm2624926d1_6k.htm"},"events":[{"id":32204,"run_id":29585,"accession_number":"0001104659-26-106137","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Adagene announced achievement of a preclinical milestone in its collaboration with Exelixis, triggering a $2.0 million milestone payment and selection of additional SAFEbody ADC candidates. This is a material operational/partnership milestone that demonstrates progress in a strategic collaboration and generates near-term cash, but does not fit the discrete event categories (not M\u0026A, not a discrete financing, not a clinical trial result announcement). The milestone achievement and associated payment represent meaningful progress in the company's pipeline development strategy.","company_name":"Adagene Inc.","ticker":"ADAG","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":[{"id":35317,"accession_number":"0001104659-26-106137","item_number":"EX-99.1","item_title":"tm2624926d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Adagene announced achievement of a preclinical milestone in its collaboration with Exelixis, triggering a $2.0 million milestone payment and selection of additional SAFEbody ADC candidates. This is a material operational/partnership milestone that demonstrates progress in a strategic collaboration and generates near-term cash, but does not fit the discrete event categories (not M\u0026A, not a discrete financing, not a clinical trial result announcement). The milestone achievement and associated payment represent meaningful progress in the company's pipeline development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T12:01:17.262878+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35317,"accession_number":"0001104659-26-106137","item_number":"EX-99.1","item_title":"tm2624926d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Adagene announced achievement of a preclinical milestone in its collaboration with Exelixis, triggering a $2.0 million milestone payment and selection of additional SAFEbody ADC candidates. This is a material operational/partnership milestone that demonstrates progress in a strategic collaboration and generates near-term cash, but does not fit the discrete event categories (not M\u0026A, not a discrete financing, not a clinical trial result announcement). The milestone achievement and associated payment represent meaningful progress in the company's pipeline development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T12:01:17.262878+00:00","company_name":"Adagene Inc.","ticker":"ADAG","filing_date":"2026-09-09"}]}